AmFAR, Foundation for AIDS Research: Treat Asia HIV Observational Database (TAHOD)

Project Timeline

2008 – Now

TREAT Asia has pioneered the first database to assess the natural history of HIV disease in treated and untreated patients throughout Asia and the Pacific. In an unprecedented regional collaboration on HIV research, 17 clinical sites in Cambodia, China, Hong Kong, India, Indonesia, Japan, Malaysia, the Philippines, Singapore, South Korea, Taiwan, and Thailand are using standardized methods to collect anonymous patient data.

The information gathered through the TREAT Asia HIV/AIDS Observational Database (TAHOD) is intended to inform the development of more effective research and treatment programs, and ultimately could help to define treatment standards for Asia and the Pacific—standards that may differ from those in Europe and the U. S. The database seeks in the long term to improve HIV clinical data collection throughout the region, assist in evaluating new HIV treatments, monitor antiretroviral and prophylactic treatment as it relates to demographics and markers of HIV disease stage, monitor toxicity related to antiretroviral therapy, and examine HIV’s natural history, including the relationship between access to antiretroviral therapy and disease progression.

External Links


Other Clinical Research

Strategic Timing of Anti-Retroviral Treatment (START Study)
The START trial was designed to address the question: In HIV-1 (subsequently referred to as HIV) infected asymptomatic participants with a CD4+ count greater than 500 cells/mm3, is immediate use...
Making Drug Treatment Work: Opportunities and Challenges Towards an Evidence and Rights-Based Approach
Compulsory drug detention centers (CDDCs) are common throughout Asia. However, medical treatments for substance use disorders, such as opioid agonist treatment (OAT), are generally unavailable in these settings. In this...
Dolutegravir and Darunavir Evaluation in Adults Failing Therapy (D²EFT)
First-line antiretroviral regimens are safe, effective and easily administered (one pill taken once daily). Even so, the annual failure rate is around 10-15% of treated patients. Second-line regimens have a...